Machine Perfusion in Split Liver Transplantation: A Scoping Review.
- 1Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
Abstract
Background
Split liver transplantation (SLT) maximizes donor organ utilization but faces challenges with ischemia-reperfusion injury (IRI). Machine perfusion techniques, including hypothermic oxygenated perfusion (HOPE), dual HOPE (DHOPE), and normothermic machine perfusion (NMP), may enhance graft viability and expand the donor pool. This scoping review maps existing clinical and experimental evidence on machine perfusion in SLT, examining benefits, feasibility, outcomes, and knowledge gaps.Methods
Following Joanna Briggs Institute manual guidelines, we searched PubMed, Embase, Scopus, and Web of Science through September 3, 2025, plus gray literature (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Google Scholar). Studies exploring machine perfusion techniques in liver splitting of human or animal grafts, with or without transplantation, were included.Results
After screening 958 records, 38 studies were included (29 primary studies, 9 reviews). Among primary studies, 84 clinical transplant cases using machine perfusion were identified (including 2 cases with unspecified perfusion modality); however, this number may not represent unique patients because of possible overlap between same-center cohorts. HOPE (7 studies, 40 cases) was supported by preliminary comparative data suggesting reduced IRI versus static cold storage, with 1 cohort study showing lower postreperfusion syndrome rates (13.3% versus 47.1%, P = 0.04) and reduced IRI scores (3 versus 4, P = 0.03). NMP (16 studies, 34 cases) enabled extended preservation up to 25 h with 100% short-term graft survival in case series. DHOPE (4 studies, 8 cases) reported feasibility for complex full-left/full-right splitting. Evidence was limited by small sample sizes (median n = 2, range 1-26), short follow-up (maximum 18 mo, median 6 mo), absence of randomized trials, and potential publication bias.Conclusions
Machine perfusion remains an investigational strategy in SLT. Preliminary evidence suggests HOPE may reduce IRI and NMP may provide logistical advantages through extended preservation. However, evidence derives entirely from small observational studies without randomization. Multicenter prospective studies with standardized protocols, longer follow-ups, and cost-effectiveness analyses are needed.
Related
- First Split Liver Transplantation Using VitaSmart Hypothermic Machine Perfusion in the United States.
- Machine Perfusion and Oncologic Outcomes After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
- Cell-Based and Cell-Derived Therapies Delivered During Ex Vivo Machine Perfusion for Solid Organ Reconditioning Prior to Transplantation: A Systematic Review
- The potential biomarkers of organ transplantation in the era of machine perfusion: Current status, challenges, and future directions
- Beating heart transplantation after normothermic machine perfusion: A single institution experience.
BibTeX
@article{daher2026machine,
title = {{Machine Perfusion in Split Liver Transplantation: A Scoping Review.}},
author = {Abdullah Daher and Mohammed Naga and Konrad Kobryń and Michał Grąt},
journal = {Transplantation direct},
year = {2026},
month = oct,
doi = {10.1097/txd.0000000000002021},
url = {https://europepmc.org/article/MED/42948557},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Machine Perfusion in Split Liver Transplantation: A Scoping Review.
AU - Abdullah Daher
AU - Mohammed Naga
AU - Konrad Kobryń
AU - Michał Grąt
PY - 2026
DA - 2026/10/26
JO - Transplantation direct
DO - 10.1097/txd.0000000000002021
UR - https://europepmc.org/article/MED/42948557
AB - Background Split liver transplantation (SLT) maximizes donor organ utilization but faces challenges with ischemia-reperfusion injury (IRI). Machine perfusion techniques, including hypothermic oxygenated perfusion (HOPE), dual HOPE (DHOPE), and normothermic machine perfusion (NMP), may enhance graft viability and expand the donor pool. This scoping review maps existing clinical and experimental evidence on machine perfusion in SLT, examining benefits, feasibility, outcomes, and knowledge gaps.Methods Following Joanna Briggs Institute manual guidelines, we searched PubMed, Embase, Scopus, and Web of Science through September 3, 2025, plus gray literature (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Google Scholar). Studies exploring machine perfusion techniques in liver splitting of human or animal grafts, with or without transplantation, were included.Results After screening 958 records, 38 studies were included (29 primary studies, 9 reviews). Among primary studies, 84 clinical transplant cases using machine perfusion were identified (including 2 cases with unspecified perfusion modality); however, this number may not represent unique patients because of possible overlap between same-center cohorts. HOPE (7 studies, 40 cases) was supported by preliminary comparative data suggesting reduced IRI versus static cold storage, with 1 cohort study showing lower postreperfusion syndrome rates (13.3% versus 47.1%, P = 0.04) and reduced IRI scores (3 versus 4, P = 0.03). NMP (16 studies, 34 cases) enabled extended preservation up to 25 h with 100% short-term graft survival in case series. DHOPE (4 studies, 8 cases) reported feasibility for complex full-left/full-right splitting. Evidence was limited by small sample sizes (median n = 2, range 1-26), short follow-up (maximum 18 mo, median 6 mo), absence of randomized trials, and potential publication bias.Conclusions Machine perfusion remains an investigational strategy in SLT. Preliminary evidence suggests HOPE may reduce IRI and NMP may provide logistical advantages through extended preservation. However, evidence derives entirely from small observational studies without randomization. Multicenter prospective studies with standardized protocols, longer follow-ups, and cost-effectiveness analyses are needed.
SN - 2373-8731
ER -